Takeda Pharmaceutical Company Limited

Morihisa Saitoh

Yasufumi Wada

Masato Yoshikawa

Toshitake Kobayashi

Nobuyuki Negoro

Tomohiro Seki

Yoshihisa Nakada

Masaki Seto

Hiroshi Nara

Akito Shibuya

Michiyo Mochizuki

Zenyu Shiokawa

Yusuke Tominari

Kosuke Hidaka

Yasuo Nakagawa

Yayoi Nakayama

Taisuke Kato

Tsuneo Oda

Yusuke Sasaki

Paul D Greenspan

Brian Scott Freeze

Taisuke Tawaraishi

Masashi Yamasaki

Shumpei Murata

Naomi Kitamoto

Taisuke Katoh

Atsutoshi Okabe

Takahiro Tanaka

Hiromi Kobayashi

Norihito Tokunaga

Taku Kamei

Eiji Kimura

Jun Kunitomo

Masanori Okaniwa

Tetsuya Tsukamoto

Fumio Itoh

Tomohiro Kawamoto

Takafumi Yukawa

Takatoshi Yogo

Yusuke Ohba

Katsuhito Murase

Hiroyuki Nagamiya

Yayoi Yoshitomi

Hiroki Iwashita

The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

Methods of making a cyclic dinucleotide

Antibody-drug conjugates comprising a cyclic dinucleotide

Cyclic dinucleotide

The present invention provides a heterocyclic compound having an RIP1 kinase inhibitory action, which is useful for the prophylaxis or treatment of Gaucher's disease, Niemann-Pick disease, inflammatory bowel disease, multiple sclerosis, chronic kidney disease, acute kidney injury, acute hepatic failure, autoimmune hepatitis, hepatitis B, hepatitis C, alcohol steatohepatitis, non-alcohol steatohepatitis and the like. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Heterocyclic compound

Provided is a compound, such as ethyl 6-((2-chloro-4-fluorobenzyl)sulfonyl) -3-hydroxycyclohex-1-ene-1-carboxylate or an optical isomer thereof, having a superior Toll-like receptor 4 (TLR4) signaling inhibitory action, which may be useful as a prophylactic or therapeutic drug for diseases such as autoimmune diseases and/or inflammatory diseases, or chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver failure, and ischemia reperfusion injury (IRI).

Cyclic compound

The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: wherein, each symbol is explained in greater detail in the specification.

Cyclic compounds

The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).

The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

For the purpose of providing a GSK-3&#x3b2; inhibitor containing an oxadiazole compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3&#x3b2;-related pathology or disease, the present invention provides a GSK-3&#x3b2; inhibitor containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

GSK-3&#x3b2; inhibitor

Growing community of inventors

Kanagawa, Japan

Morihisa Saitoh